These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7252979)

  • 1. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
    J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.
    Manning M; Olma A; Klis WA; Kolodziejczyk AM; Seto J; Sawyer WH
    J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
    Manning M; Olma A; Klis WA; Seto J; Sawyer WH
    J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
    J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
    Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
    J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
    Lammek B; Bankowski K; Misicka A; Manning M; Seto J; Sawyer WH
    J Med Chem; 1989 Jan; 32(1):244-7. PubMed ID: 2909737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
    Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
    J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization of renal vasopressin-stimulated adenylate cyclase by a vasopressor and antidiuretic antagonist, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-ethyl)-D-tyrosine, 4-valine]arginine vasopressin.
    Chang P; Kimura K
    Biochem Biophys Res Commun; 1987 Apr; 144(2):770-8. PubMed ID: 3579941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
    Lowbridge J; Manning M; Haldar J; Sawyer W
    J Med Chem; 1977 Sep; 20(9):1173-6. PubMed ID: 926117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.
    Lowbridge J; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Mar; 21(3):313-5. PubMed ID: 628009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and receptor specificities of vasopressin antagonists.
    Manning M; Sawyer WH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S29-35. PubMed ID: 2434768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs.
    Schwartz J; Liard JF; Ott C; Cowley AW
    Am J Physiol; 1985 Nov; 249(5 Pt 2):H1001-8. PubMed ID: 3840655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the vasopressin antagonist d/CH2/5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin.
    László FA; Csáti S; Baláspiri L
    Acta Endocrinol (Copenh); 1984 May; 106(1):52-5. PubMed ID: 6730854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro effects of arginine-vasopressin receptor antagonists on the hypothalamic-pituitary-adrenal axis in the rat.
    Bernardini R; Chiarenza A; Kamilaris TC; Renaud N; Lempereur L; Demitrack M; Gold PW; Chrousos GP
    Neuroendocrinology; 1994 Nov; 60(5):503-8. PubMed ID: 7845540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.